Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson.
Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 77% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $130,505 and 6, calls, for a total amount of $278,695.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $130.0 to $160.0 for Johnson & Johnson over the last 3 months.
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson & Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson & Johnson's substantial trades, within a strike price spectrum from $130.0 to $160.0 over the preceding 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
JNJ | CALL | SWEEP | BEARISH | 09/20/24 | $3.8 | $3.65 | $3.69 | $155.00 | $92.3K | 7.1K | 85 |
JNJ | PUT | TRADE | BEARISH | 12/18/26 | $6.9 | $4.1 | $6.9 | $130.00 | $69.0K | 6 | 0 |
JNJ | CALL | SWEEP | BULLISH | 08/16/24 | $0.57 | $0.55 | $0.57 | $160.00 | $45.5K | 14.9K | 1.1K |
JNJ | CALL | TRADE | BULLISH | 01/16/26 | $13.6 | $12.15 | $13.6 | $155.00 | $43.5K | 284 | 32 |
JNJ | CALL | TRADE | BULLISH | 07/26/24 | $2.19 | $2.02 | $2.14 | $152.50 | $42.8K | 679 | 348 |
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Following our analysis of the options activities associated with Johnson & Johnson, we pivot to a closer look at the company's own performance.
5 market experts have recently issued ratings for this stock, with a consensus target price of $182.0.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson & Johnson options trades with real-time alerts from Benzinga Pro.
Posted In: JNJ